It has been suggested that Epstein-Barr virus (EBV) might suppress antibody maturation either by facilitating bypass of the germinal center reaction or by inhibiting hypermutation directly. However, by infecting the Burkitt's lymphoma (BL) cell line Ramos, which hypermutates constitutively and can be considered a transformed analogue of a germinal center B cell, with EBV as well as by transfecting it with selected EBV latency genes, we demonstrate that expression of EBV gene products does not lead to an inhibition of hypermutation. Moreover, we have identified two natural EBV-positive BL cell lines (ELI-BL and BL16) that hypermutate constitutively. Thus, contrary to expectations, EBV gene products do not appear to affect somatic hypermutation.
Epstein-Barr virus (EBV) is a nearly ubiquitous human gammaherpesvirus which possesses growth-transforming capabilities and which naturally infects and persists within the immune system's B-cell compartment. Viral infection can be studied in infectious mononucleosis patients, where the virus is detectable in blood and lymphoid tissues, notably tonsils. Many infected B cells express the full viral latency gene repertoire seen in EBV-transformed B lymphoblastoid cell lines (LCLs) in vitro, including six EBV-determined nuclear antigens (EBNA1, -2, -3A, -3B, -3C, and -LP), three latent membrane proteins (LMP1, -2A, and -2B), and several highly expressed, nonpolyadenylated RNAs (EBER and Bam A RNAs) (14) . However, distinct, more restricted latency gene expression patterns have been detected (2, 3, 7) and may contribute significantly to lifelong viral persistence.
Antibodies provide a valuable line of defense against bacteria, parasites, and viruses. Much of this defense's strength is afforded by the sheer size of the B-cell-encoded antibody repertoire, which is created by two distinct processes. First, V(D)J recombination imprecisely juxtaposes the gene segments encoding the immunoglobulin (Ig) variable (V) region, thereby creating a large primary antibody repertoire. Second, in response to antigen, the primary repertoire is further diversified by somatic hypermutation, which, coupled with selection, produces a pool of antibodies that bind with high affinity to encountered antigens. Somatic hypermutation is largely restricted to Ig gene V regions and occurs primarily during a narrow window of B-cell development in germinal centers. Antigen-specific B cells can develop further into antibodysecreting plasma cells or long-lived memory cells poised for subsequent immune challenges.
Two lines of investigation have suggested that EBV might be capable of preventing B cells from mutating their Ig V genes.
First, EBV-positive cells from infectious mononucleosis patients, although present at a high frequency within tonsils, are found rarely in tonsillar germinal centers, suggesting that this stage of development is either bypassed or inhibited (12) . In support of this, mice expressing LMP1 lack obvious germinal centers, a phenotype attributable to perturbed signaling by CD40, a B-cell surface receptor required for germinal center formation (9, 22) . Second, a study recently published by Kurth and colleagues classified individual tonsillar B cells with respect to expressed EBV latency genes and Ig V region DNA sequences, from which both the cellular differentiation stages and dynastic relationships could be inferred (10) . This approach revealed evidence of preferential ongoing somatic hypermutation in EBV-negative as opposed to EBV-positive tonsillar B cells, which suggested that EBV might possess the capacity to stop Ig gene somatic hypermutation directly (10) . Consistent with this, Denépoux and coworkers were able to induce somatic hypermutation in two EBV-negative BL cell lines (BL2 and BL45) but not in an EBV-positive BL cell line (BL74) (4) .
Reasoning that a molecular understanding of the apparent immutability of EBV-positive B cells could provide key insights into an important facet of EBV biology and also an entry point that could be exploited to investigate the somatic hypermutation mechanism, we undertook experiments designed to test specifically whether EBV gene products can indeed suppress Ig V gene somatic hypermutation.
Selected EBV latency protein expression in Ramos has no effect on hypermutation. To test whether EBV latency gene products directly suppress Ig gene hypermutation, we transfected Ramos (an EBV-negative [8] , constitutively hypermutating [19] BL cell line) with puromycin-resistant constructs expressing EBNA1, the only latency protein expressed ubiquitously in latently EBV-infected cells and a plausible candidate because it is the sole viral protein required for latent replication of the EBV genome (25) and therefore must recruit cellular factors for efficient DNA replication (e.g., human singlestrand binding protein [hSSB] [27] ), and EBNA-LP (1), an early-expressed coregulator of transcription and therefore also a reasonable candidate (13, 21) . Ramos was also transfected with a construct expressing LMP1 (11), a presumed negative control but, as mentioned above, possibly interesting. If one of these candidate EBV gene products was capable of suppressing hypermutation, transfectants expressing it presumably would cease ongoing V H and V L mutation. This phenotype can be assayed by staining cells with R-phycoerythrin-conjugated goat anti-human IgM ( chain specific; Sigma) and measuring the generation of surface IgM (sIgM)-negative variants by flow cytometry (FACSCalibur and CellQuest; Becton Dickinson); such sIgM-negative variants in the parental cell line Ramos are attributable mostly to the frequent generation of stop codons in the Ig V H domains by hypermutation (19) .
Ramos transfectants expressing each selected latency protein were established by electroporation (300 V, 950 F; BioRad Gene Pulser II), selected in medium containing 2 g of puromycin (Sigma) per ml, continuously cultured for at least 1 month, and analyzed for the generation of sIgM-negative variants. Compared to Ramos transfected with vector only, cells expressing either EBNA1 or EBNA-LP generated similar median percentages of sIgM-negative variants, indicating that the hypermutation program remained intact (Fig. 1A and D) . Ramos transfectants expressing LMP1 also displayed normal levels of sIgM-negative variants (Fig. 1A and D) . Latency protein expression was confirmed by immunofluorescence microscopy of methanol-fixed cells (EBNA1 and EBNA-LP), Western blotting (EBNA1 and LMP1) (Fig. 1B) , and flow cytometric analysis of paraformaldehyde-fixed NP-40-permeablized cells (EBNA-LP) (Fig. 1C) . Thus, expression of EBNA1, EBNA-LP, or LMP1 alone appeared insufficient to block hypermutation.
Infection of Ramos with EBV has no effect on its mutability. To investigate whether other EBV gene products (such as EBER RNAs, Bam A RNAs, or other latency proteins) might abrogate hypermutation or whether specific latency gene products might act in concert to do so, we analyzed Ramos derivatives generated by de novo infection with EBV-neo, a derivative of the Akata type 1 EBV containing a selectable neomycin cassette (20) . High-titer virus prepared and generously provided by C. Dawson (University of Birmingham) was used to infect Ramos essentially as described previously (20) ; infectants were selected in medium containing 2 mg of Geneticin per ml and confirmed by EBNA1 Southern hybridization. Analysis of two representative infectants, EBV1 and EBV19, revealed that, contrary to expectations, they also generated significant numbers of sIgM-negative variants, implying that the capacity for ongoing hypermutation was unaffected. Sub- cloning and fluctuation analyses demonstrated that there was indeed no apparent difference in the frequencies of sIgMnegative variants generated ( Fig. 2A) . Twenty-one other new infectants also produced sIgM-negative variants (data not shown).
Wondering whether the apparently intact hypermutation programs of EBV1 and EBV19 could be attributed to expression of a restricted (or nonexistent) latency gene repertoire, we probed extracts prepared from EBV1 and EBV19 with latency protein-specific antibodies. In addition to the aforementioned primary antisera, PE2 (anti-EBNA2 [26] ) and HG/RS22 (human sera which recognize type 1 EBV EBNA3A-C [18] ) were used. In most instances, infection of an EBV-negative BL cell line such as Ramos results in the establishment of a viral latency in which only EBNA1 and the noncoding RNAs are expressed (23) . EBV19 displayed, as expected, this type of latency profile in which only EBNA1 was found (Fig. 2B) . However, EBV1 defined another class of Ramos infectant, more LCL-like, in which nearly all latency genes were expressed, including EBNA3A-C (Fig. 2B) . Thus, expression of neither a restricted nor a complete latency gene repertoire via de novo EBV infection seemed to affect hypermutation in Ramos. Some naturally EBV-positive BL cell lines also mutate constitutively. Given that hypermutation proceeded normally in Ramos infected with EBV as well as in the presence of selected EBV gene products, we wondered whether it would be possible to identify naturally occurring EBV-positive B-cell lymphomas that mutate their Ig genes constitutively during culture. A survey of naturally occurring EBV-positive BL cell lines revealed an absence of a clearly identifiable population of sIgMnegative variants among many of them (e.g., Akata, BL74, Chep, Daudi, Raji, and Wan). However, a clear sIgM-negative population was noted in two of these EBV-positive cell lines, ELI-BL and BL16, suggesting an intrinsic hypermutation capacity (Fig. 3A) . ELI-BL harbors a type 2 EBV, resembles germinal center B cells, and expresses a latency gene repertoire consisting only of EBNA1 and the noncoding EBER and Bam A RNAs (17) . BL16 also contains a type 2 virus, but, in contrast to ELI-BL, it appears more LCL-like and expresses a full latency gene repertoire (references 15 and 17 and data not shown).
Although a clear sIgM-negative population was visible in ELI-BL and BL16 cultures, it was important to address whether these could be attributed to bonafide hypermutation. Fluctuation analysis of ELI-BL subclones revealed that the sIgM-negative variants were indeed being generated at high frequency during in vitro culture (Fig. 3B) , and V H sequence analysis (using protocols defined previously [19] ) in the case of BL16 subclones confirmed that this instability reflected somatic hypermutation (Fig. 3C) . Considerable V H sequence diversity, including several sequences with multiple base substitution mutations, and an overall high V H mutation frequency of 0.0014 mutation per base pair indicated that hypermutation is ongoing in BL16. Moreover, despite the relatively small number of V H sequences sampled, one dynastic relationship could be inferred (first mutation at Gly54 [GGT-GAT] and second mutation at Val92 [GTG-ATG]). Finally, like in Ramos, most of the BL16 V H base substitution mutations occurred at G or C nucleotides (24 of 33 [73%] ) and clustered within the complementarity-determining regions (Fig. 3C) . Thus, several hallmarks of ongoing hypermutation were also distinguishable in two natural EBV-positive BL cell lines, one expressing a limited and the other expressing a full latency gene repertoire. It was therefore clear that somatic hypermutation could proceed unabated in the presence of EBV. It is clearly interesting, in the light of our results, to reconsider the lack of ongoing hypermutation in EBV-positive tonsillar B cells shown by Kurth et al. (10) . One possibility is that this lack of mutation does not reflect a direct association with the continued presence of EBV in these B cells but is a consequence of other pathological changes associated with infectious mononucleosis. Thus, for example, the lack of ongoing Ig V gene hypermutation in these cells could be simply because B-cell clonal expansion has occurred at a memory (postgerminal center) stage. Alternatively, there could be some circumstances in which EBV gene products might suppress hypermutation, but these remain to be defined.
Although earlier screens for hypermutating B-cell lines suggested that only EBV-negative cell lines might be capable of constitutive hypermutation (4, 19) , the work described here reveals that EBV-positive BL cell lines can be also highly proficient. That this was not observed before may be due to the significant heterogeneity in BL cell line hypermutability reported here for EBV-positive lines and previously for EBVnegative cell lines (19) .
A bonus from these studies has been the identification of two constitutively hypermutating human B-cell lines (ELI-BL and BL16), both of which are EBV positive. The only BL cell line previously shown to perform constitutive hypermutation was Ramos (19) . The pattern of hypermutation performed in BL16 appears to be very similar to that in Ramos. Such G/Ctargeted mutations are likely to constitute one part of the hypermutation program executed by human B cells in vivo (19) . The results also suggest that ongoing Ig V gene hypermutation may not be such a rare attribute among BL cell lines. This identification enables a comparison of a wider panel of mutating and nonmutating BL cell lines and should facilitate further advances in understanding the molecular mechanism of somatic hypermutation.
